Tag Archives: Indian Patent Office

Bayer appeals against compulsory licence order

Posted on May 7, 2012 by

Source: Livemint C.H. Unnikrishnan, 5 May 2012 German drug maker Bayer HealthCare AG has appealed against the compulsory licence granted to Natco Pharma Ltd to manufacture and market cancer drug Nexavar by India’s Controller General of Patents. Bayer filed its … Continue reading →

Posted in Compulsory Licensing | Tagged , , , | Leave a comment

Official Statement by Government of India on TRIPS flexibilties

Posted on May 4, 2012 by

In an official press release, Ministry of Chemicals and Fertilizers, Government of India stated that “the Government has recently decided to invoke the flexibility under the World Trade Organisation (WTO) agreement on trade related Intellectual Property Rights for compulsory licensing of … Continue reading →

Posted in Compulsory Licensing, TRIPS flexibilities | Tagged , | Leave a comment

Bayer withdraws writ petition against Natco’s CL application

Posted on November 25, 2011 by

24-11-11 Source: Livemint C.H. Unnikrishnan Bayer had in the writ petition challenged the Indian patent office’s decision to publish Natco’s compulsory licensing application for public review Mumbai: In a new twist to the ongoing legal battle between German drug multinational … Continue reading →

Posted in Compulsory Licensing | Tagged , , , , | Leave a comment

Press Statement: NOVARTIS LIES THREATEN OUR LIVES ACT UP-BASEL LAUNCHED TO DECLARE THE WAR ON PHARMA

Posted on October 17, 2011 by

● Press Statement ● ACT UP-BASEL ● Sunday the 16th October 2011 http://actupbasel.org/actupbasel/ BASEL, SWITZERLAND – Tomorrow in New Delhi, the next hearing of the case brought by the Basel-based pharmaceutical firm Novartis against the Indian government is scheduled to … Continue reading →

Posted in patent evergreening, Sec 3 (d), TRIPS | Tagged , , , , | Leave a comment

MSF Briefing Note: WHAT NOVARTIS SAYS…AND WHY IT’S WRONG

Posted on October 5, 2011 by

Médecins Sans Frontières briefing note, 4 October 2011  Swiss pharmaceutical company Novartis issued a press statement last week in response to the growing concerns regarding its latest legal challenge against the Indian government. Ahead of the next hearing of the … Continue reading →

Posted in Indian Patent Law, patent evergreening, Sec 3 (d) | Tagged , , , | 1 Comment

Natco Pharma’s compulsory license application for Cancer Drug- Sorafenib Tosylate

Posted on September 23, 2011 by

Recently, Natco Pharma, an Indian generic company had applied for Compulsory License (CL) to produce and sell the generic verson of Bayer’s patented cancer drug Sorafenib Tosylate (Brand name-Nexavar).This drug is used in the treatment for liver and kidney cancer. … Continue reading →

Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities | Tagged , , , , , | 2 Comments

Stephen Colbert on faux innovation by pharma companies to extend patents

Posted on September 19, 2011 by

We have been posting many articles on Novartis case in Supreme Court challenging Section 3(d) of Indian patent law which inhibits patent evergreening. Here is an interesting video that explains evergreening of patents by pharmaceutical companies in a very funny way. It … Continue reading →

Posted in patent evergreening, Sec 3 (d) | Tagged , , , | Leave a comment

A victory for Novartis could spell death for millions

Posted on September 7, 2011 by

Source: The Hindu PRISCILLA JEBARAJ Sepetember 6,2001 The Swiss pharma giant fighting in Supreme Court for patent on anti-cancer drug A case being heard in the Supreme Court on Tuesday could signal a death sentence for Loon Gangte. Mr. Gangte … Continue reading →

Posted in Drug Pricing, Indian Patent Law, patent evergreening, Sec 3 (d) | Tagged , , , , | 1 Comment

Drug company Novartis tries to weaken Indian patent law that protects people

Posted on September 5, 2011 by

  Geneva/New Delhi 5 September 2011 – Novartis will go before the Indian Supreme Court tomorrow in the latest attempt by the Swiss multinational pharmaceutical company to undermine a key public health safeguard in Indian patent law specifically designed to prevent … Continue reading →

Posted in Indian Patent Law, Sec 3 (d), TRIPS plus | Tagged , , , , | Leave a comment